Akeso Enrolls First Patient in Innovative Breast Cancer Study with HER3 ADC AK138D1 and Ivonescimab
Akeso has announced the enrollment of the first patient in a Phase Ib/II clinical trial evaluating its next-generation HER3 antibody-drug conjugate AK138D1 in combination with Ivonescimab for breast cancer treatment. This study represents a significant advancement in the company's IO2.0 + ADC2.0 strategy, aiming to improve therapeutic outcomes for patients.